Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

INTRODUCTION: The phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). OBJECTIVE: Our objective is to provide updated...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drug Saf
Main Authors: Kato, Terufumi, Seto, Takashi, Nishio, Makoto, Goto, Koichi, Yamamoto, Noboru, Okamoto, Isamu, Tao, Liang, Yu, Wei, Khaznadar, Tarik, Tajima, Kosei, Shibata, Masahiko, Seki, Akihiro, Yamamoto, Nobuyuki
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2017
Assuntos:
Original Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808045/
https://ncbi.nlm.nih.gov/pubmed/29043496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-017-0596-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares